ADR detection using Artificial intelligence(AI)

Authors: [1] Aneesh Mohamed khader, [2] Banu Sri Balasubramanian, [3] Premnath Marappan Sekar, [4] Silpadas Kozhissery Punnakkal, [5] Udhaykrishna Kakkuzhiyil Muraleedharan.

[(1,2,3,4&5)] Department of Pharmacy, KMCH College of Pharmacy, Coimbatore, India.

Corresponding author: Udhaykrishna kakkuzhiyil Muraleedharan.

Abstract

Background:

Adverse drug reactions (ADRs) are a significant problem in healthcare, and they cause increased morbidity, mortality, and healthcare expenses. Despite the fact that traditional pharmacovigilance systems are very vital in post-marketing surveillance of drug safety, they have been characterized by underreporting, slow signal recognition, and the inability to process large and cumbersome data.

Objective:

This paper seeks to summarize how artificial intelligence (AI) and machine learning methods can be used to improve the process of detecting, monitoring, and evaluating adverse drug reactions and to outline the potential benefits of the new technologies compared to the existing pharmacovigilance procedures.

Methods:

An overview of the literature on the existing knowledge of pharmacovigilance practices, their drawbacks, and the recent use of AI-based techniques was carried out in the form of a narrative review. The most important methods of AI, such as machine learning, deep learning, and natural language processing, were discussed in the framework of structured and unstructured healthcare data sources to identify ADR.

Results:

The methods of AI-guided pharmacovigilance are found to be more efficient, sensitive, and scalable in the ADR signal detection as it allows the automated analysis of massive amounts of real-world data. Machine learning, natural language processing, and early detection of safety signals are some of the techniques that will help to improve risk stratification, utilization of electronic health records, spontaneous reporting systems, and clinical narratives. Nevertheless, there are issues of data quality, model interpretability and regulatory acceptance.

Conclusion:

Artificial intelligence can greatly enhance the pharmacovigilance systems by supplementing the conventional ADRs detection systems. AI-based methods can help to promote more proactive, precise, and patient-centered drug safety surveillance with the proper validation, ethical control, and regulatory directions.

Abbreviations:

ADR – Adverse Drug Reaction
AI – Artificial Intelligence
ML – Machine Learning
DL – Deep Learning
NLP – Natural Language Processing
SRS – Spontaneous Reporting System
ICSR – Individual Case Safety Report
FAERS – FDA Adverse Event Reporting System
WHO – World Health Organization
PSUR – Periodic Safety Update Report
PBRER – Periodic Benefit-Risk Evaluation Report
EHR – Electronic Health Record
ROC – Receiver Operating Characteristic
AUC – Area Under the Curve
EMA – European Medicines Agency

Keywords: Artificial Intelligence, Adverse Drug Reactions, Machine Learning, Natural Language Processing, Signal Detection, Drug Safety.

1.Introduction

Medical products are a major factor in preventing and treating diseases but one of the conditions that is inevitably related to their use is adverse drug reaction (ADR). ADRs are a major contributor to morbidity, mortality, and escalated healthcare expenses, and are considered to be a serious reason of patient injury across the globe. Although the development of drugs and their regulation have improved, ADRs remain critical issues on patient safety in all healthcare environments (1).

The complexity of the modern pharmacotherapy adds to the burden of ADRs. Polypharmacy, older age, prevalence of chronic diseases and the common use of high-risk drugs among the general population have significantly contributed to the increased chances of adverse outcomes. The elderly patients and those with numerous comorbidities are highly vulnerable because of the impaired pharmacokinetics, pharmacodynamics, and drug-drug interactions (1,2).

Though clinical trials, which are necessary in assessing the effectiveness and safety of new medicines, are not intended to identify all the potential ADRs. The size of samples, duration of the study, controlled conditions and limiting eligibility criteria limit their capacity to detect rare, delayed or population specific adverse effects. As a result, most of the clinically relevant ADRs are discovered when drugs enter into normal clinical practice (3).

The gaps have necessitated the creation of pharmacovigilance systems to oversee the safety of drugs during the post-marketing processes. Conventional pharmacovigilance is based on using the following approaches: spontaneous reporting systems, observational studies, and manual case assessment. Although these approaches have played a critical role in the detection of material safety indicators, they are usually limited by underreporting, reporting delays, data quality concerns, and the increasing amount of healthcare data (4).

Over the past few years, the ADR detection has been provided with new opportunities by the rapid development of electronic health records, social media, and massive healthcare data sets. The developments have stimulated a growing interest in artificial intelligence (AI) and machine learning-based methods to improve signal detection, automating data analysis, and assist in timely making regulatory decisions. The incorporation of AI into pharmacovigilance systems is likely to offset the longstanding shortcomings of the traditional paradigm and enhances the safety of drugs monitoring in the real environment (5).

2. Overview of adverse drug reaction

The problem of adverse drug reactions (ADRs) is still a pertinent issue in the contemporary healthcare sector, which influences patient safety, treatment effectiveness, and the use of healthcare resources. ADRs are generally explained as unintended and adverse reactions to drugs that happen in the course of normal clinical use, and they are not associated with medication abuse and overdose (6). They are one of the primary causes of avoidable morbidity, and they are becoming a key measure of quality of healthcare.

The ADRs formation is multifactorial and depends on the drug-related and patient-specific factors. Pharmacodynamic and pharmacokinetic properties of drugs, dose intensity, therapy duration, and drug-drug interactions are some of the factors that may contribute to adverse outcomes. The age, sex, genetic polymorphisms, dysfunction of organs, comorbidities and polypharmacy are other variables related to patients that also confound individual susceptibility to ADRs (7,8).

Clinically, ADRs are very heterogeneous in the way they are manifested. The reactions are predictable and linked to the established pharmacological effect of the drug and others are unpredictable and involve immunological or idiosyncratic events. ADRs can have mild to severe or fatal outcomes, which might require minimal intervention or hospitalization and termination of treatment respectively (9).

Although significant scrutiny is applied in the drug development process, pre-marketing clinical trials do possess limitations in terms of the detection of the entire array of potential ADRs. Safety findings cannot be generalized due to small sample sizes, controlled studies, and brief follow-ups as well as not including vulnerable groups. This has led to a large number of ADRs being detected only after a drug has been extensively used in clinical practice, and in particular, a large number of these are rare, delayed-onset reactions, or population-specific reactions (10).

Pharmacovigilance systems are thus needed to monitor on the emergence of safety issues during the life cycle of a drug. Early identification and evaluation of ADRs is important in maximizing benefits/ harms, regulation decision-making, and enhancement of patient-centred care (11).

3. Classification of adverse drug reaction

Adverse drug reactions (ADRs) classification offers a conceptual framework which can be used to gain an insight into the different patterns in which medicines may lead to harm. Since clinical manifestations, severity, and underlying mechanisms of ADRs differ greatly, classification systems are needed to provide a systemic evaluation, reporting, and prevention of ADRs in pharmacovigilance practice (12).

The ADR classification is meant to assist in making clinical and regulatory safety decisions. Using adverse reaction organization based on common features like predictability, dose relationship, mechanism, and temporal association, healthcare professionals can anticipate potential risks more likely and put in place the necessary measures in terms of monitoring. It is also a method of separating between preventable reactions and unpredictable ones that must be intensively followed up after the product is introduced to the market (13).

Mechanism-based considerations are at the centre of consideration of ADR. Part of the reactions are the direct effect of the known pharmacology of a drug, and some are independent of dose or therapeutic effect and may be immunological or genetic in nature. It is important to distinguish between these patterns as it determines the clinical management approaches, risk reduction measures, and the safety data interpretation (14).

Another significant measure used to classify ADRs is time course. Some of these side effects are seen in close relation to exposure to the drugs and others are seen after long use or after discontinuation of the use of the drug. The understanding of delayed or cumulative reactions is important especially in long-term therapies since in most cases, they are not detected until clinical trials in pre-marketing phases (3).

Pharmacovigilance ADR classification allows the detection of standardized data collection and signals across both spontaneous reporting systems and observational studies. It allows

a steady coding, comparison of safety signals between populations, as well as, prioritization of regulatory measures. Furthermore, the classification systems can offer a platform to complementary analytic strategies, such as artificial intelligence-driven models that are based on structured definitions to detect and forecast the adverse drug safety trends out of extensive real-life data (5). (Figure: 1)



(Figure: 1 Classification of adverse drug reactions)

4. Traditional methods of ADR detection

Adverse drug reactions (ADRs) have historically been detected through proven pharmacovigilance methods used to observe drug safety following its authorization in the market. These approaches mainly rely on systematic data gathering, clinical observation and regulatory reporting and are still at the heart of post-marketing drug surveillance.

The spontaneous reporting system (SRS) is the most popular of the conventional methods. Within this system, healthcare professionals, patients, and pharmaceutical companies are required to submit suspected ADRs voluntarily to regulatory organizations at the national or international level. Individual case safety reports (ICSRs) submitted to databases like the FDA Adverse Event Reporting System (FAERS), the VigiBase database maintained by WHO, and the EudraVigilance database can be used to identify possible safety concerns in the use of a drug in the real world. One of the areas where spontaneous reporting has been useful is in identification of rare, serious and unexpected ADRs which may not have been detected during pre-marketing clinical trials (12,15).

The other significant conventional approach is clinical trials that are done prior to drug approval. Phase I-III clinical tests give organized information of safety in a controlled environment and assist in revealing general and dose-related adverse reactions. Nevertheless, such trials are generally limited in sample size, duration and are carefully chosen populations which can limit their potential to determine rare, delayed, or population-specific ADRs (16).

Cohort studies and case-control studies are also post-marketing observational studies that aid ADR detection. These research works investigate the use of drugs and related adverse events in practice in actual clinical conditions and provide an opportunity to evaluate drug safety in more global assumptions among various patient groups. Even though the results of such studies are of good epidemiological quality, they may be time-consuming and resource-intensive, and may be confounded by factors that create confounding effects (17).

Another traditional source of safety information is represented by case reports and case series. Such descriptive reports can be the initial report of ADRs not recognized before and lead to a follow-up. Although they are useful in generating signals, they are not generalizable due to their anecdotal nature, and cannot be used to give conclusive results about causality (18).

Moreover, marketing authorization holders are required by regulatory authorities to provide periodic safety reports to them, including periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs), etc. These reports are cumulative safety data summaries over specified intervals and help in continued assessment of the benefit-risk profile of a drug. Nevertheless, they rely mostly on the already reported data and fail to identify the emerging ADRs in real-time (15).

In general, the conventional ways of ADR detection have been very instrumental in the identification of drug-related risks and safeguarding the patient. However, the dependence on passive reporting, inaccessibility of data timely and less representation of real-life populations shows the need to adopt complementary strategies to enhance pharmacovigilance systems.

5. Limitations of conventional pharmacovigilance

The basis of post-marketing drug safety surveillance in the world is traditional pharmacovigilance systems especially spontaneous reporting systems (SRS). Although the use of these systems has a long history of regulatory acceptance, they have a number of inherent constraints that decrease their ability to identify adverse drug reactions (ADRs) in a time-sensitive, comprehensive, and dependable way.

Massive under-reporting of ADRs is one notable weakness of traditional pharmacovigilance. The available published data shows that only a minimal number of the actual adverse reactions are reported to the reporting databases with estimates often indicating that only 10% or less are reported (4,19). This is caused by various reasons such as lack of awareness by health care workers, lack of causality in attribution, lack of time to report and even the sense that the mild reactions or previously known reactions do not justify reporting. The outcome is that the safety signals will not be identified or did not manifest themselves until a long time has passed (19).

In addition to low reporting frequency, incompleteness and poor quality of reported reports are also a significant challenge. Most spontaneous reports do not provide critical clinical information including dosage used, treatment period, time lag between the exposure to the drug and onset of the adverse effect and the outcome of the patient after the discontinuation of the therapy. Lack of such information limits the usefulness of signal analysis and compromises the usefulness of causality analysis, and thus, reduces the overall usefulness of pharmacovigilance systems (20).

The other inherent weakness is the inability to draw causal links between medications and reported adverse events. Spontaneous reporting systems are also observational in nature and do not make use of standardized methods of causal verification. The widespread presence of confounding factors, such as polypharmacy, comorbid conditions and disease progression, also makes it difficult to determine the actual drug effects and can lead to spurious safety signals (12).

Besides, the traditional pharmacovigilance databases have no denominator data, where they record the reported adverse events but do not include the number of people who were exposed to a particular drug. It is such that it is impossible to determine the actual extent of drug-related harm because it cannot be accurately calculated when the incidence rates and relative risks are not known. Therefore, spontaneous reporting data can only be used as an instrument of hypothesis testing as opposed to conclusive assessment of risk (21).

Bias and heterogeneity in reporting also play an important role in affecting reliability of the traditional pharmacovigilance information. Newer drugs and other adverse events that are of regulatory or media interest are more likely to be reported, and older drugs and familiar reactions are under-represented. Variations in reporting behavior by healthcare

systems and geographic area also serve to increase the number of inconsistencies that make it difficult to compare safety data meaningfully (4).

Delay in detection of safety indications is another issue of interest. Spontaneous reporting is passive in nature and will require manual data analysis; thus, it is possible that it will take a long time before the regulatory action is taken. Uncommon reactions, cumulative toxicities, or other adverse events with late manifestations are especially vulnerable to recognition late, and may result in patients being exposed to avoidable risks (15).

Lastly, traditional pharmacovigilance systems do not offer much representation of real patients. Vulnerable groups, which include older adults, children, pregnant women, and those with multiple comorbidities are poorly reflected in clinical trial data and even spontaneous reports. This is limited representation which restricts the generalizability of findings on safety and constrinds the individual risk assessment that can be made in the usual healthcare practice (12).

Combined, these constraints support the necessity of sophisticated analytics models that are able to handle a large volume of heterogeneous healthcare data. The future of pharmacovigilance is seen in the emerging artificial intelligence-based methods to better signal detection efficiency and data quality issues, as well as proactive drug safety surveillance.

6. Rationale for using artificial intelligence in ADR detection

Drug safety surveillance has increased dramatically in size and complexity over the last few years, and has put additional pressure on traditional pharmacovigilance systems. Conventional methods such as spontaneous reporting and manual review of signals have been very instrumental in the process of detecting critical safety issues. But these techniques are often restricted by underreporting, delays in reporting and difficulties in processing large and varied data. Consequently, clinical significance of adverse drug reactions (ADRs) is seldom identified on time in most environments (4).

The increasing supply of practical healthcare information has also increased the necessity of more effective analysis mechanisms. Electronic health records, insurance claims, clinical registries, and patient-reported data, in general, are valuable in the presence of the information on drug safety. Nevertheless, these data sources are so large and diverse that it becomes more and more ineffective to analyze them using traditional means. Advanced computational methods are applicable to perform the systematic analysis of high-volume data and to identify relationships between the exposure to drugs and the occurrence of adverse events that are not evident when the traditional surveillance methods are used (22).

Another problem of pharmacovigilance is that the proportion of safety-related data is too large to be captured in structured forms, including clinical narratives and free-text reports.

These data cannot be easily assessed only through manual review. Techniques of computational text analysis allow obtaining important clinical data in unstructured sources, which increases the evidence base used in the detection of ADRs, and in the implementation of more comprehensive safety analyses (23).

Another factor of drug safety monitoring is timeliness. The traditional pharmacovigilance usually depends on the retrospective data that could slow the occurrence of safety signals. Analytical models may be used to develop data-driven data processing to undertake the continuous monitoring of incoming safety data to prioritise and identify potential risks earlier. This is especially valuable to identify uncommon or slow adverse reactions that may not be apparent upon a small-scale clinical application (5).

Lastly, there is the adoption of sophisticated methods in analysis that can be used to develop more elaborate assessments of the benefit-risk profiles between various groups of patients. These approaches can help make prescribing safer and more risk-focused to reduce the risks of being susceptible to particular ADRs in patients, as they can be able to identify subgroups that are more vulnerable to them. Such methods are becoming a part of the current pharmacovigilance systems as the regulatory agencies increasingly focus on the use of real-world evidence (24).

7. Data Sources for AI-Based ADR Detection

The concept of artificial intelligence (AI) has become a key component of contemporary pharmacovigilance, as it can analyze the information about the safety of drugs in large-scale and automate the process of identifying adverse drug reactions (ADRs). Structured pharmacovigilance data, including spontaneous reporting systems and healthcare databases are extensively analyzed by machine learning methods (25,26). Unsupervised learning algorithms are typically used to identify drug-event relationships using labeled safety data whereas supervised learning algorithms are typically used to identify unexpected or rare ADR signals without predetermined outcomes. The methods increase sensitivity of the signals and decrease the use of the traditional disproportionality methods that are usually restricted in dealing with complex and high-dimensional data (27).

Another fundamental AI method used in pharmacovigilance is natural language processing (NLP), especially to identify the information on ADR in the unstructured data. NLP techniques can be used to automatically identify drug names, adverse events, and context information in clinical narratives, regulatory reports and biomedical literature (23,27). According to recent reviews, the utilization of deep learning-based NLP models to enhance accuracy in entity recognition and relationship extraction is on the rise, enabling the wider capture of safety facts missing in structured databases on their own (25,29).

Non-convolutional neural networks or transformer based architectures are further advances in pharmacovigilance as they provide an opportunity to integrate various multimodal data.

Structured clinical data and unstructured textual information can be processed simultaneously by these models, which can assist with more powerful ADR prediction and signal prioritization. Besides this, hybrid AI methods involving the integration of information-driven learning and knowledge-driven systems are becoming a more popular topic to enhance comprehensibility and regulatory accountability (21). In general, recent review articles find that AI methods have a substantial positive effect on the efficiency, scalability, and speed of pharmacovigilance operations, but issues of transparency, quality of data, and validation are important factors to consider during practical use (25,28).

8. Artificial Intelligence Techniques in Pharmacovigilance

The concept of artificial intelligence (AI) has become the key element of contemporary pharmacovigilance, providing the ability to analyze large-scale drug safety data automatically and enhance the process of adverse drug reactions (ADRs) detection. Structured pharmacovigilance data (including Spontaneous reporting system and healthcare databases) are commonly analyzed using machine learning methods. To infer the relationship between drugs and events as indicated by safety data through the use of labeled data, the use of supervised learning algorithms is common, and to identify an unexpected or rare ADR sign, unsupervised learning methods are utilized. The methods amplify the sensitivity in signal detection and minimize the dependence on the conventional disproportionality methods that are in most cases constrained in processing multifaceted and high-dimensional data (25,30).

Natural language processing (NLP) is another fundamental AI method used in pharmacovigilance, especially that which helps to extract ADR-related information in unstructured data sources. The NLP techniques allow the automatic identification of drug names, adverse events, and situational context of the clinical narratives, regulatory reports, and biomedical literature. Recent surveys point to a growing trend in the application of deep learning-based NLP models in order to enhance the target accuracy of the entity recognition and relationship extraction to further encompass the amount of real-life safety information that would be overlooked without structured databases only (31,32).

By making it possible to combine multimodal data of different sources, deep learning methods such as neural networks and transformer-based architectures have also contributed to the advancement of pharmacovigilance. Such models are capable of handling both structured clinical information and textual data that are not structured at the same time and aid in better ADR prediction and signal prioritization. Besides, data-driven learning combined with knowledge-based systems is also discussed more often as a hybrid AI method to enhance interpretability and regulatory acceptance. In general, the recent review articles find that AI methods have a significant positive effect on the efficiency, scalability, and timeliness of pharmacovigilance operations, but issues with transparency, data quality,

and validation have to be considered as the major challenges to real-world implementations (30,33).

9. Machine Learning Approaches for ADR Detection

The use of machine learning (ML) in the field of pharmacovigilance has become more popular to improve the detection of adverse drug reactions (ADR) through the analysis of big and heterogeneous datasets that are challenging to analyze with traditional statistical methods. ML algorithms can be used to automatically learn complicated associations between drugs and adverse events using real-world data sources like the spontaneous reporting system, electronic health records, and claims databases. ADR classification and prediction ADR classification and prediction are extensively applied using supervised ML where models are trained with labeled data to identify cases of real ADRs versus background. The most used algorithms are logistic regression, decision trees, random forests and gradient boosting models which have been shown to be more sensitive and specific than the more traditional disproportionality-based approaches (34,35).

Unsupervised machine learning algorithms are essential in the process of detecting exploratory signals especially in cases where there are fewer or no labeled data. These are non-parametric techniques that find hidden structures and abnormal patterns in pharmacovigilance data, which do not have predefined outcomes. The algorithms and techniques used in dimensionality reduction allow finding rare or new ADR signals, grouping similar drug-event patterns and pointing out the anomalies that can reflect previously unidentified safety issues (36). These methods are particularly useful when conducting early post-marketing surveillance of new ADRs, where such new ADRs may not be well documented.

Recent reviews also focus on the increasing use of ensemble and hybrid ML models that take on a combination of a number of algorithms to enhance robustness and predictive performance. The ML-based ADR detection models could help to personalize the risk assessment by incorporating various variables and characteristics of patients, their comorbidities, the history of medications, and time-associated exposure patterns. In spite of these developments, there are still issues among them such as imbalance of data, low interpretability as well as a necessity to validate them through external validation in different healthcare environments. However, the literature review always reports that the efficiency and timeliness of ADR detection with the use of ML are significantly improved relative to the classical pharmacovigilance practices (35,37).

10. Deep Learning Models for ADR Signal Identification

The advent of deep learning (DL) models has been a potent data mining method of adverse drug reaction (ADR) signal detection because it can build non-linear relationships on large and high-dimensional pharmacovigilance datasets that might be extremely complex to detect without an automatic learner. In contrast to other machine learning techniques that use a significant amount of manual feature engineering, deep learning systems are capable of directly operating on raw structured and unstructured data, which makes them more effective at detecting ADR and scalable. Models based on neural networks such as feed-forward neural networks, recurrent neural networks, and transformer-based models have been used in a spontaneous reporting system and electronic healthcare database to detect the association between drugs and events and rank safety signals with enhanced sensitivity (38).

Deep learning has proved itself especially effective at processing unstructured textual data using natural language processing software. The systematic reviews indexed in PubMed have demonstrated that deep learning and state-of-the-art NLP models can significantly enhance the quality of adverse event events extraction among clinical stories, regulatory reports, and practical healthcare data relative to conventional rule-based or less deep learning systems (38,39). These models can have the ability to model contextual, semantic, and temporal relations that are critical to the correct ADR signal recognition.

Besides the text analysis, deep learning models facilitate the notion of multimodal identification of ADR signals in the context of integrating heterogeneous data sets, including spontaneous reports, electronic health records, and patient-generated data. These integrated methods would strengthen and increase the generalization of ADR signals in various healthcare environments. Irrespective of these benefits, literature review has raised issues regarding interpretability, huge amounts of data, and regulatory certification. However, the use of deep learning-based methods is becoming an established part of the next-generation pharmacovigilance systems (40,41).

11. Role of Natural Language Processing in ADR Detection

The Natural language processing (NLP) has emerged as an important enabling technology in adverse drug reaction (ADR) detection since it enables automated analysis of unstructured textual data that is generated by various parts of healthcare systems. A significant percentage of ADR related data is documented in free text (spontaneous report accounts, clinical notes, discharge report and regulatory reports), which cannot be easily retrieved by organized pharmacovigilance databases. With the help of NLP methods, it is possible to convert this unstructured text into structured forms as drug names, adverse

events, symptoms, and contextual data are identified to enhance the completeness and sensitivity of ADR detection (31,35).

As NLP techniques using machine learning have developed, pharmacovigilance systems have changed away from rule-based text processing in favor of a data-driven system capable of better dealing with linguistic variation and clinical complexity. Reviews that are indexed by PubMed indicate that NLP models using clinical narrative and safety reporting can substantially boost ADR signal detection over and above using structured data analysis. The methods are especially useful in identifying rare, delayed or complex ADRs that would otherwise be underreported (42).

NLP is finding more and more application to biomedical literature and patient textual data mining to aid in early detection of safety signals. NLP-based literature screening can be used to speed up the process of identifying ADR evidence in case reports and observational studies, whereas patient-reported experience analysis can offer additional real-world evidence on drug safety profiles. Even though the issues associated with the terms normalization, negation management, and data quality still persist, the literature review has always shown that NLP is a necessity in the context of contemporary AI-driven pharmacovigilance systems (35,43).

12. AI-Based Tools and Platforms for ADR Monitoring

Pharmacovigilance has seen increased adoption of AI-based services and technologies that are used to improve the monitoring, detection, and management of adverse drug reactions (ADRs). Conventional ADR surveillance frameworks are based on manual review of cases and statistical signaling of cases which may be time-intensive and scale-based. Pharmacovigilance platforms based on AI can automatically process significant aspects of the data sharing process by combining machine learning, natural language processing, and data-mining models to process information in spontaneous reporting systems, electronic health records, biomedical literature, and patient-generated sources. Such platforms contribute to around the clock and close to real-time ADR monitoring and facilitate the identification and prioritization of safety cues earlier (39,44).

There exist a number of pharmacovigilance systems based on AI to process the individual case safety report (ICSR), such as case intake, coding, and detecting duplication and prioritizing signals. Artificial intelligence-driven decision-support tools support the work of safety experts by prioritizing the possible signals, pointing out the clinically meaningful patterns, and aiding the experts instead of substituting them. The literature that is indexed in PubMed states that these tools enhance efficiency, consistency, and transparency in monitoring ADRs and that they remain consistent with general pharmacovigilance requirements (44,45).

Large scale signal detection and benefit-risk assessment is also becoming a widespread application of AI-based platforms. These systems combine and use sophisticated analytics to uncover new drug safety issues in populations and geographical areas using the data of several sources. The visualization dashboards and the alerting systems go further to help the pharmacovigilance experts to interpret intricate safety information and aid regulatory decision making. Despite the inherent issues of validation, explainability, and regulatory acceptance, the published evidence continuously demonstrates that AI-based tools and platforms will be one of the significant steps toward more proactive and scalable ADR monitoring systems (39,46).

13. Evaluation Metrics for AI Models in Adverse Drug Reaction Detection

Assessment of the artificial intelligence (AI) models trained to detect adverse drug reactions (ADR) is a decisive measure in establishing the efficacy of these models and their suitability to be used in pharmacovigilance. Since ADR monitoring is a safety-critical task, the evaluation metrics should not be based on predictive accuracy alone, but also include class imbalance, clinical relevance, and model generalizability. The majority of ADR detection systems are presented as binary classification systems, which require the application of several performance measures that are complementary (39).

Performance evaluation is based on metrics that are based on the confusion matrix. The accuracy or proportion of correct predictions is frequently reported but can give minimal information in pharmacovigilance datasets, in which non-ADR cases greatly exceed the ADR cases (25). As a result, increased focus is made on sensitivity (recall), which is used to estimate the percentage of the true ADR cases that the model is able to pick up. High sensitivity is more especially critical in drug safety monitoring where the inability to identify ADRs can delay regulatory intervention or cause harm to patients (47).

Precision or positive predictive value is a measure of the percentage of the ADRs being predicted is a true ADR and is critical in reducing falsity of safety signals which would otherwise result in unnecessary investigations and regulatory overload. To achieve the desired sensitivity and precision, other studies use the value of F1, a harmonic mean, which gives a single, interpretable measure of model performance, particularly with imbalanced datasets which are often seen in pharmacovigilance research (21).

In addition to these measures related to threshold, receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) are commonly used to determine the discriminative capacity of AI models at different decision thresholds. The higher the values of AUC, the better the results of the program in differentiating between ADR and non-ADR cases. The results of a few studies that conducted the evaluation of machine learning models on both spontaneous reporting systems and electronic health records have indicated

moderate to high AUC values, which is why it can be assumed that AI can be useful in ADR detection (30,39).

Precision-recall curves and area under the precision-recall curve are increasingly being suggested in datasets having extreme imbalance in classes. These measures deal with the outcomes of the minority ADR group and should be regarded as more informative than ROC-based in the conditions of real-life pharmacovigilance. Besides the choice of metrics, model validation strategies are also very important in evaluation. Internal validation, e.g. cross-validation, is used to curb the impact of overfitting but external validation with independent datasets is used to estimate the strength and applicability of ADR detection models to suit different populations and reporting regimes (25,47).

All in all, an integrated analysis based on the ideas of sensitivity, precision, F1 score, AUC, and precision-recall rates, validated on a metal level, will offer a complete assessment system of AI-based ADR detection models. These measures are important elements that need to be carefully chosen and reported in order to translate the advances in computational methods into quality pharmacovigilance tools.

14. Applications of Artificial Intelligence in ADR Detection

The field of artificial intelligence has entered the industry playing a significant supportive role in pharmacovigilance, especially by eliminating the shortfalls of conventional adverse drug reaction surveillance techniques. Traditional methods are largely based on spontaneous reporting, which tends to lead to incomplete clinical data, late identification of signals and underreporting. The analysis of the large-scale and sophisticated healthcare data helps to identify the medication safety signals earlier and more consistently, as AI-based methods provide the opportunity to analyze numerous datasets.

Automated signal detection in pharmacovigilance databases is one of the most important uses of AI in ADR detection. Machine learning algorithms are able to work with large amounts of individual case safety reports and discover statistically significant drug-event relationships more effectively than the conventional disproportionality methods. With AI, the sensitivity of the signals is increased with a lower rate of false positives, which means that safety issues are detected earlier. Also, automation will decrease the use of manual case review, resulting in regulatory process efficiency and enhanced operational effectiveness in post-marketing surveillance (48).

It has been the focus of a growing body of research on the use of machine learning algorithms to make predictions on adverse drug reactions using structured clinical and pharmacological data. Random forests, support machine, gradient boosting models, and neural networks are all algorithms that are trained with patient demographics, drug characteristics, dosage information and lab measurements. These models show high

predictive validity in determining persons who are at greater risk of taking ADRs and help in implementing preventive risk-management and personalized pharmacovigilance (49).

ADR-related information is found in large quantities in unstructured textual forms in the form of clinical stories, discharge reports, spontaneous reporting descriptions, biomedical literature. The methods of natural language processing can be used to extract the relevant entities such as drug names, adverse events, and temporal relationships automatically out of the free-text information. State-of-the-art deep learning NLP models have been found to do better in ADR recognition and classification. NLP expands the pharmacovigilance scope using the unstructured data and improves the production of real-world evidence (40).

The tendencies are focused on developing hybrid AI schemes that combine both structured and unstructured information. These are models that fuse Pascal machine learning methodologies with deep learning-based NLP systems to represent both numerical clinical as well as textual contextual information. Hybrid architectures have exhibited a high level of performance in ADR detection over single-modality approaches, especially in more complex clinical trial and real-world datasets. These integrated systems would give a more detailed appreciation of the drug safety profiles and enhance the strength of the signal detection procedure (50).

Besides signal detection, AI has also been used to aid causality in pharmacovigilance. Knowledge-based and probabilistic artificial intelligence models help to determine the probabilities of causal relationships between drug exposure and adverse events. Such techniques involve use of clinical evidence, patient specific factors and prior knowledge to minimize subjectivity and enhance consistency in causality determination particularly in complex cases that may involve polypharmacy or rare adverse events (51).

Continuous monitoring of real-world data sources is also possible with the help of AI technologies, which include electronic health records, registries, and observational databases. Through longitudinal patient data, AI systems can find new ADR trends that could not be seen in pre-marketing clinical trials. This will enhance surveillance after the marketing of a product and contributes to regulatory decision-making during the product life cycle (52).

15. Challenges and Limitations of AI-Based ADR Detection

The development of artificial intelligence has improved at a high pace in detecting adverse drug reactions, although it is faced by numerous limitations that restrict its strength and effectiveness in pharmacovigilance. The quality and the completeness of the data that is used to train AI models is a basic limitation. The sources of pharmacovigilance data often have a problem of underreporting, loss of clinical data, inappropriate terminology, and bias of reporting. Such problems with data may bring adverse impacts on the model

performance, causing biased predictions and lower sensitivity, especially of rare or delayed ADRs (48,49).

The other significant issue is that the higher AI models do not seem to be very interpretable, especially the deep learning algorithms. Most ADR detection systems that are based on AI are black-box models, which do not provide much information about the way the prediction or the safety signal is created. This type of transparency lowers the clinical trust and makes it harder to win the favor of the regulatory board because the pharmacovigilance decisions are made based on clear and explainable evidence to take correct safety measures (40,52).

Their applicability to other populations and medical environments also is a matter of concern in terms of AI models. The performance of models trained with data of a particular area or health care system may not be the same when implemented in other geographic, ethnic, or clinical settings. Differences in prescribing behavior, genetic variation, health care structure, and reporting behaviour can greatly impact the model accuracy and therefore continuous retraining and external validation is required (49,50).

Also, AI-driven ADR detection systems can find mostly statistical relationships between drugs and adverse events and not necessarily causal relationships. Detection of associations can be affected by confounding variables including comorbidities, polypharmacy and disease progression which predispose the risk of giving false-positive signals. Still, expert review, and frameworks of complementary causality assessment are crucial to the proper interpretation of AI-generated findings (51).

The implementation of AI in pharmacovigilance is also complicated by issues related to operational, ethical, and regulatory issues. The usage of AI tools in the current safety monitoring systems involves interoperability, standard validation tasks, and compliance with regulations. There are also some concerns of privacy, cybersecurity, and ethical responsibility in the use of patient-level data. The absence of standard regulatory principles towards AI validation remains a hindrance to the mass adoption (52).

Lastly, over dependence on AI generated outputs can lead to automation bias, as the human assessors may overtrust algorithmic advice and underestimate clinical experience. The AI-based systems are thus supposed to be employed as a decision-support system and not substitutes of expert judgment. The benefit of maintaining human control, openness, and skeptical analysis is necessary to make the AI safe and responsible in ADR detection (48,52).

16. Ethical, Legal, and Regulatory Considerations in ADR Detection using Artificial Intelligence (AI)

AI has become the new weapon in pharmacovigilance to detect adverse drug reactions (ADRs), offering a possibility to analyze big and complex data, including

spontaneous reporting systems, electronic health records, and unstructured clinical narratives, with the help of machine learning and natural language processing. AI enhances the sensitivity and timeliness of signal detection but its use also produces significant ethical issues concerning patient privacy, confidentiality, transparency, and bias. Big clinical and real-world datasets to train AI models need to be de-identified safely to maintain sensitive patient data, and the black-box characteristics of most AI algorithms are problematic to the ethics of transparency and explainability in clinical decision-making. Also, the skewed or incomplete training data can result in unfair ADR detection among various patient groups that could affect the safety of patients and their confidence in AI-assisted pharmacovigilance systems (53,54).

Law wise, AI-based ADR detection throws light on issues of data ownership, permission to further use health data and legal responsibility where AI assisted systems overlook material safety indicators or make false projections. The conventional legal systems dealing with medical negligence and product liability are yet to establish accountability when automated or semi-autonomous AI is involved in making safety-related decisions. It is therefore imperative to ensure that the national and international data protection laws are followed to prevent legal consequences of mishandling the patient data to carry out pharmacovigilance (55).

Regarding the regulatory factors, regulatory bodies note that AI-based pharmacovigilance should be subjected to intensive validation, constant control, and reports to prove consistency and repeatability. The tools are now only suggested to assist, and not substitute, human experience in signal identification and appraisals, and retain human supervision in pharmacovigilance procedures. Nevertheless, the lack of globally aligned regulatory frameworks on self-learning AI models is still a serious challenge, and it is important to emphasize the necessity of developing new frameworks to moderate innovation and ethical protection and patient safety (56).

17. Future Perspectives and Emerging Trends in AI-Based ADR Detection

The future of adverse drug reaction (ADR) detection is anticipated to be greatly improved by the growing adoption of the artificial intelligence (AI), especially, with the help of the machine learning methods that can access extensive and complicated pharmacovigilance data. New developments point to the further combination of different information sources like electronic health records, biomedical literature, registries, and patient-reported outcomes to enhance the completeness and sensitivity of safety signals detection. Text mining and natural language processing techniques that use AI are actively being utilized on unstructured data to facilitate smoother recognition of underreported ADRs that are frequently not recognized via traditional spontaneous reporting models (5,57).

The other significant future-oriented view is the shift to predictive pharmacovigilance where AI models would not only identify current safety signals but also predict which drug-patient combinations are likely to result in adverse reactions or pose risks and identify this before extensive clinical use. These predictive strategies facilitate the use of early risk reduction plans and are in line with personalized medicine because they introduce patient-specific components like demographics, comorbidities and treatment patterns. Moreover, the appearance of the adaptive AI systems with the ability to learn constantly based on the new safety data available allows more dynamic and near real-time tracking of drug safety during the product lifecycle (25).

Regarding regulatory and implementation perspectives, the focus on building transparent, interpretable, and validated AI models is increasingly growing to guarantee the trust and acceptance of AI by healthcare experts and regulators. The future pharmacovigilance systems will perhaps entail increased cooperation of regulatory bodies, academia, and pharmaceutical companies to develop standard assessment models and systems of governance of AI-based ADR detection systems. Although there are still issues associated with data quality, interoperability, and control, these new trends portend the promise of AI to enhance early signal detection, benefit-risk analysis, and patient safety (5,23).

18. Conclusion

Patient safety is still a serious problem of adverse drug reactions and despite the fact that the use of traditional pharmacovigilance systems is necessary, they are hampered by underreporting, slow signal recognition and limited use of real-life information. Artificial intelligence application in the pharmacovigilance industry is potentially a solution as it allows analyzing large and complicated health data effectively, enhancing signal detection, and allowing to identify the adverse drug reaction earlier using machine learning and natural language processing algorithms. Nevertheless, data quality, interpretability and ethical and regulatory issues continue to arise and it is recommended that AI is used as a decision support mechanism and not meant to replace human judgment. In general, AI-based solutions can potentially improve the pharmacovigilance of drugs and facilitate more proactive, accurate, and patient-centered practices.

References

1. Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2014 Apr;22(2):83–94.

2. Salvi F, Marchetti A, D'Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf. 2012 Jan;35 Suppl 1:29–45.

3. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016 Feb 4;14:10.

4. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.

5. Bate A, Hobbiger SF. Artificial Intelligence, Real-World Automation and the Safety of Medicines. Drug Saf. 2021 Feb;44(2):125–32.

6. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016 Oct;16(5):481–5.

7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200–5.

8. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PloS One. 2009;4(2):e4439.

9. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005 Aug;5(4):309–16.

10. Loke YK, Price D, Herxheimer A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007 Jul 5;7:32.

11. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S73-77.

12. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255–9.

13. Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf. 2010 Jan 1;33(1):15–23.

14. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15–9.

15. WHO importance of pharmacovigilance [Internet]. Available from: https://www.who.int/publications/i/item/10665-42493

16. Rawlins MD. Clinical pharmacology. Adverse reactions to drugs. Br Med J. 1981 Mar 21;282(6268):974–6.

17. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005 Apr;58(4):323–37.

18. Vandenbroucke JP. Case reports in an evidence-based world. J R Soc Med. 1999 Apr;92(4):159–63.

19. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96.

20. Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017 Jul;16(7):761–7.

21. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform. 2015 Apr;54:202–12.

22. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013 Jun;93(6):539–46.

23. Kreimeyer K, Foster M, Pandey A, Arya N, Halford G, Jones SF, et al. Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review. J Biomed Inform. 2017 Sep;73:14–29.

24. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol. 2019;51(6):373–6.

25. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012 Jun;91(6):1010–21.

26. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427–36.

27. Warrer P, Hansen EH, Juhl-Jensen L, Aagaard L. Using text-mining techniques in electronic patient records to identify ADRs from medicine use. Br J Clin Pharmacol. 2012 May;73(5):674–84.

28. Coloma PM, Trifirò G, Patadia V, Sturkenboom M. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013 Mar;36(3):183–97.

29. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016 May 10;3:160026.

30. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012 Mar 14;4(125):125ra31.

31. Nikfarjam A, Sarker A, O'Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc JAMIA. 2015 May;22(3):671–81.

32. Wang Y, Wang L, Rastegar-Mojarad M, Moon S, Shen F, Afzal N, et al. Clinical information extraction applications: A literature review. J Biomed Inform. 2018 Jan;77:34–49.

33. Li Y, Salmasian H, Vilar S, Chase H, Friedman C, Wei Y. A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records. J Am Med Inform Assoc JAMIA. 2014;21(2):308–14.

34. Caster O, Juhlin K, Watson S, Norén GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf. 2014 Aug;37(8):617–28.

35. Luo Y, Thompson WK, Herr TM, Zeng Z, Berendsen MA, Jonnalagadda SR, et al. Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review. Drug Saf. 2017 Nov;40(11):1075–89.

36. Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Transact A Math Phys Eng Sci. 2018 Sep 13;376(2128):20170356.

37. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.

38. Li Y, Tao W, Li Z, Sun Z, Li F, Fenton S, et al. Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. J Biomed Inform. 2024 Apr;152:104621.

39. Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017 Feb;83(2):227–46.

40. Li Y, Tao W, Li Z, Sun Z, Li F, Fenton S, et al. Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. J Biomed Inform. 2024 Apr;152:104621.

41. Jagannatha AN, Yu H. Bidirectional RNN for Medical Event Detection in Electronic Health Records. Proc Conf Assoc Comput Linguist North Am Chapter Meet. 2016 Jun;2016:473–82.

42. Meystre SM, Savova GK, Kipper-Schuler KC, Hurdle JF. Extracting information from textual documents in the electronic health record: a review of recent research. Yearb Med Inform. 2008;128–44.

43. Demner-Fushman D, Elhadad N. Aspiring to Unintended Consequences of Natural Language Processing: A Review of Recent Developments in Clinical and Consumer-Generated Text Processing. Yearb Med Inform. 2016 Nov 10;(1):224–33.

44. Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne JM, et al. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nat Rev Drug Discov. 2014 May;13(5):395–7.

45. Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009 Apr;14(7–8):343–57.

46. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998 Jun;54(4):315–21.

47. Coloma PM, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):611–21.

48. Warner J, Prada Jardim A, Albera C. Artificial Intelligence: Applications in Pharmacovigilance Signal Management. Pharm Med. 2025 May;39(3):183–98.

49. Dsouza VS, Leyens L, Kurian JR, Brand A, Brand H. Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients. Res Soc Adm Pharm RSAP. 2025 Jun;21(6):453–62.

50. Khemani DB, Malave DS, Shinde S, Shukla M, Shikalgar R, Talwar H. AI-driven pharmacovigilance: Enhancing adverse drug reaction detection with deep learning and NLP. MethodsX. 2025 Dec;15:103460.

51. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. Int J Clin Pharm. 2025 Aug;47(4):932–44.

52. Nagar A, Gobburu J, Chakravarty A. Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration. Ther Adv Drug Saf. 2025;16:20420986251361435.

53. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. Pharm Med. 2022 Oct;36(5):295–306.

54. Rudnisky E, Paudel K. Pharmacovigilance in the Era of Artificial Intelligence: Advancements, Challenges, and Considerations. Cureus. 2025 Jun;17(6):e86972.

55. Desai MK. Artificial intelligence in pharmacovigilance - Opportunities and challenges. Perspect Clin Res. 2024;15(3):116–21.

56. Barbieri MA, Battini V, Carnovale C, Cocco M, Papoutsi DG, Heckmann NS, et al. Artificial intelligence in pharmacovigilance signal management: a review of tools, implementations, research, and regulatory landscape. Expert Opin Drug Saf. 2026 Feb;25(2):207–22.

57. Trifirò G, Sultana J, Bate A. From Big Data to Smart Data for Pharmacovigilance: The Role of healthcare Databases and Other Emerging Sources. Drug Saf. 2018 Feb;41(2):143–9.